Abbott Laboratories (ABT): What to Expect from Q1 2026 Earnings
Key Takeaways
- Analysts expect Q1 2026 adjusted EPS of around $1.15, up about 5% from $1.09 in Q1 2025.
- Consensus revenue forecast stands at approximately $11.0 billion, reflecting 6.4% year-over-year growth.
- Abbott's own guidance for Q1 adjusted EPS is $1.12–$1.18, aligning closely with Wall Street views.
- Key focus areas include diabetes care devices like FreeStyle Libre, medical devices growth, and nutrition segment performance.
- Full-year 2026 guidance projects organic sales growth of 6.5%–7.5% and adjusted EPS of $5.55–$5.80.
- Stock has shown mixed reactions to past earnings, with average implied moves around 4%.
Earnings Context and Why It Matters
As I review Abbott Laboratories (ABT), a diversified healthcare leader spanning diagnostics, medical devices, nutrition, and established pharmaceuticals, its fiscal quarters align neatly with the calendar year. The Q1 2026 earnings report, set for April 16 before the market opens, arrives against a backdrop of resilient demand in high-growth areas like continuous glucose monitors (CGM) and electrophysiology devices. Following full-year 2025 adjusted EPS of $5.15 (up 10%) and sales of $44.3 billion, I'm watching closely for signs of sustained momentum. This report is particularly important because it will test Abbott's ability to manage headwinds in diagnostics from declining COVID-19 testing while capitalizing on growth in diabetes care and structural heart devices, all amid intensifying competition in the medtech space.
Earnings Expectations
Wall Street's consensus points to Q1 2026 adjusted diluted EPS of $1.14–$1.17, according to sources like Zacks and MarketBeat, marking an increase from $1.09 a year earlier. Revenue expectations sit at $10.99–$11.02 billion, representing 6.4% growth over Q1 2025's $10.36 billion. Abbott's own guidance for Q1 EPS is $1.12–$1.18, with full-year adjusted EPS projected at $5.55–$5.80, implying about 10% growth at the midpoint. In Q1 2025, ABT beat on EPS but slightly missed revenue targets. The company has a track record of meeting or exceeding EPS estimates in recent quarters. From what I see, the real insights will come from segment performance: Diabetes Care (FreeStyle Libre CGM sales), Medical Devices (electrophysiology and heart failure), Nutrition (pediatric and adult products), and Diagnostics (core lab excluding COVID). Organic sales growth outside of COVID testing remains a critical metric, especially after strengths like the 12.6% growth in Medical Devices during Q1 2025. I also checked this using Tickeron’s AI Screener to compare ABT against peers in the industry.
Market Reaction and Investor Sentiment
Investor sentiment ahead of Q1 earnings leans cautiously optimistic, supported by Abbott's solid full-year 2025 results and robust guidance, though recent stock performance—down about 20% over the past 52 weeks—adds some caution. Options pricing suggests a roughly 4% move post-earnings, in line with the historical average absolute reaction of 4.1%. Reactions have varied in the past: shares fell 7–11% after Q4 2025 on a revenue miss despite meeting EPS, while Q1 2025 was more mixed. Potential downside risks include softness in diagnostics or adjustments to guidance, but beats in diabetes care or medical devices could drive meaningful upside.
Forward Outlook and Key Factors to Monitor
Abbott's FY 2026 guidance reflects confidence, with organic sales growth targeted at 6.5%–7.5% (7% at the midpoint) and adjusted EPS of $5.55–$5.80 (10% growth at midpoint), building on the strength of its base business in 2025.
One thing that stands out post-earnings will be Medical Devices, which posted 10.4% organic growth in Q4 2025, driven by 12.5% in electrophysiology and 11.7% in diabetes care. FreeStyle Libre CGM continues to play a pivotal role as diabetes markets expand; I'll be monitoring U.S. adoption rates and international progress closely.
Progress in Nutrition, including Ensure and pediatric lines, along with double-digit growth in Established Pharmaceuticals in key markets, deserves attention. Diagnostics should show stabilization outside COVID through core lab and point-of-care advancements.
I'm also keeping an eye on broader dynamics like margin trends (with gross margin expansion in recent quarters), foreign exchange effects, and potential tariff pressures. Key catalysts ahead include the Exact Sciences acquisition closing in Q2 2026 to bolster cancer diagnostics and new approvals such as the Volt PFA system. Geopolitical risks tied to China procurement programs linger, but Abbott's diversified portfolio provides a buffer for resilience.
Discovering Opportunities with Tickeron’s AI Screener
In my own research process, I rely on Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—covering industry, market cap, indicators, price patterns, and performance metrics. This streamlines identifying trade ideas, trending stocks, breakouts, and opportunities far more efficiently than manual methods. It's become a staple in how I scan for names like ABT ahead of earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ABT in upward trend: price may jump up because it broke its lower Bollinger Band on May 11, 2026
ABT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 34 cases where ABT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where ABT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 18, 2026. You may want to consider a long position or call options on ABT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on May 15, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ABT entered a downward trend on May 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.972) is normal, around the industry mean (12.428). P/E Ratio (24.880) is within average values for comparable stocks, (50.633). Projected Growth (PEG Ratio) (1.319) is also within normal values, averaging (1.656). Dividend Yield (0.027) settles around the average of (0.023) among similar stocks. P/S Ratio (3.440) is also within normal values, averaging (35.167).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement